Patent: 8,084,493
✉ Email this page to a colleague
Summary for Patent: 8,084,493
Title: | Pharmaceutical composition of peptide drug and enzyme-inhibition compounds |
Abstract: | The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject. |
Inventor(s): | Sung; Hsing-Wen (Hsinchu, TW), Sonaje; Kiran (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA) |
Assignee: | GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW) |
Application Number: | 13/068,535 |
Patent Claims: | see list of patent claims |
Details for Patent 8,084,493
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2025-01-04 |
Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | 07/27/2016 | ⤷ Try a Trial | 2025-01-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |